NO954437L - Preparater og metoder for reparasjon og forhindring av fibrotiske skader - Google Patents
Preparater og metoder for reparasjon og forhindring av fibrotiske skaderInfo
- Publication number
- NO954437L NO954437L NO954437A NO954437A NO954437L NO 954437 L NO954437 L NO 954437L NO 954437 A NO954437 A NO 954437A NO 954437 A NO954437 A NO 954437A NO 954437 L NO954437 L NO 954437L
- Authority
- NO
- Norway
- Prior art keywords
- fibrotic
- prevention
- preparations
- repair
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5921493A | 1993-05-07 | 1993-05-07 | |
US6483193A | 1993-05-19 | 1993-05-19 | |
PCT/US1994/005156 WO1994026249A1 (en) | 1993-05-07 | 1994-05-09 | Compositions and methods for reparation and prevention of fibrotic lesions |
Publications (3)
Publication Number | Publication Date |
---|---|
NO954437L true NO954437L (no) | 1995-11-06 |
NO954437D0 NO954437D0 (no) | 1995-11-06 |
NO308507B1 NO308507B1 (no) | 2000-09-25 |
Family
ID=26738503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO954437A NO308507B1 (no) | 1993-05-07 | 1995-11-06 | Anvendelse av pyridoner for fremstilling av et farmasøytisk preparat for reparasjon og forhindring av fibrotiske skader |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0702551B1 (no) |
JP (1) | JPH08510251A (no) |
AT (1) | ATE224712T1 (no) |
AU (1) | AU687816B2 (no) |
BR (1) | BR9406461A (no) |
CA (1) | CA2161648A1 (no) |
DE (1) | DE69431433T2 (no) |
ES (1) | ES2183839T3 (no) |
NO (1) | NO308507B1 (no) |
WO (1) | WO1994026249A1 (no) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5716632A (en) * | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
JPH11501911A (ja) * | 1995-03-03 | 1999-02-16 | ビー マーゴリン、ソロモン | サイトカイン成長因子の引き起こす疾病の治療 |
WO1996040090A1 (en) * | 1995-06-07 | 1996-12-19 | University Of Southern California | Method for reducing or preventing post-surgical adhesion formation using 5-lipoxygenase inhibitors |
ES2255286T3 (es) * | 1998-08-13 | 2006-06-16 | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT CO., LTD. | Inhibicion de los procesos patogenicos relacionados con las lesiones del tejido. |
JP2002526447A (ja) | 1998-09-18 | 2002-08-20 | メファ・アクチェンゲゼルシャフト | アルキルフェニルピリドンの局所製剤 |
WO2002060446A1 (en) | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
EP1455813B1 (en) * | 2001-12-18 | 2015-07-15 | mondoBIOTECH AG | Interferon gamma in combination with a diagnostic array for use in the improved treatment of idiopathic pulmonary fibrosis |
JP4542743B2 (ja) * | 2002-12-26 | 2010-09-15 | Kdl株式会社 | ピリドン誘導体の溶液状医薬組成物 |
WO2004073680A1 (ja) * | 2003-02-21 | 2004-09-02 | Shionogi & Co., Ltd. | 液滴分散型軟膏剤 |
TW200501952A (en) * | 2003-02-21 | 2005-01-16 | Shionogi & Co | Pirfenidone gel formulations |
WO2004089283A2 (en) * | 2003-04-04 | 2004-10-21 | Intermune, Inc. | Compositions and methods for treating viral infections |
EP1683788B1 (en) | 2003-11-14 | 2012-03-21 | Shanghai Genomics, Inc. | Derivatives of pyridone and use thereof |
EA015252B1 (ru) | 2005-05-10 | 2011-06-30 | Интермьюн, Инк. | Способ модуляции стресс-активированной протеинкиназной системы |
NZ591443A (en) † | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
BRPI0712902A2 (pt) * | 2006-06-05 | 2018-10-30 | Novartis Ag | compostos orgânicos |
WO2007147297A1 (en) | 2006-06-15 | 2007-12-27 | Shanghai Genomics, Inc. | The use of derviate of pyridone for preventing and treating radioactive injury of lungs |
MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
WO2009052630A1 (en) | 2007-10-26 | 2009-04-30 | Pacific Therapeutics Ltd. | Compositions and methods for treating fibroproliferative disorders |
CN102099036B (zh) | 2008-06-03 | 2015-05-27 | 英特芒尼公司 | 用于治疗炎性疾患和纤维化疾患的化合物和方法 |
US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
AU2012212269B2 (en) * | 2011-01-31 | 2016-05-19 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
CN103917223B (zh) * | 2011-09-14 | 2017-08-08 | 盐野义制药株式会社 | 供吸入的药用组合物 |
MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
CN110452216B (zh) | 2014-04-02 | 2022-08-26 | 英特穆恩公司 | 抗纤维化吡啶酮类 |
CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
TWI745396B (zh) | 2016-07-12 | 2021-11-11 | 日商鹽野義製藥股份有限公司 | 吸入用醫藥組成物 |
MX368750B (es) | 2018-08-31 | 2019-10-15 | Cell Therapy And Tech S A De C V | Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular. |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1049411A (en) * | 1972-12-18 | 1979-02-27 | Affiliated Medical Research | N-substituted pyridone and general method for preparing pyridones |
US4052509A (en) * | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
US4042699A (en) * | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
ZA757570B (en) * | 1974-12-09 | 1977-07-27 | Affiliated Med Res | A useful n-substituted pyridone |
JPH02215719A (ja) * | 1989-02-15 | 1990-08-28 | Yamauchi Akitomo | 線維化病変組織の修復並びに線維化病変の阻止剤 |
US5310562A (en) * | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
-
1994
- 1994-05-09 WO PCT/US1994/005156 patent/WO1994026249A1/en active IP Right Grant
- 1994-05-09 AT AT94916710T patent/ATE224712T1/de not_active IP Right Cessation
- 1994-05-09 DE DE69431433T patent/DE69431433T2/de not_active Expired - Fee Related
- 1994-05-09 CA CA002161648A patent/CA2161648A1/en not_active Abandoned
- 1994-05-09 AU AU68291/94A patent/AU687816B2/en not_active Ceased
- 1994-05-09 JP JP6525629A patent/JPH08510251A/ja not_active Ceased
- 1994-05-09 EP EP94916710A patent/EP0702551B1/en not_active Expired - Lifetime
- 1994-05-09 ES ES94916710T patent/ES2183839T3/es not_active Expired - Lifetime
- 1994-05-09 BR BR9406461A patent/BR9406461A/pt not_active Application Discontinuation
-
1995
- 1995-11-06 NO NO954437A patent/NO308507B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
EP0702551A1 (en) | 1996-03-27 |
CA2161648A1 (en) | 1994-11-24 |
NO308507B1 (no) | 2000-09-25 |
BR9406461A (pt) | 1996-01-30 |
JPH08510251A (ja) | 1996-10-29 |
DE69431433T2 (de) | 2003-12-04 |
AU6829194A (en) | 1994-12-12 |
ES2183839T3 (es) | 2003-04-01 |
EP0702551A4 (en) | 1997-08-20 |
ATE224712T1 (de) | 2002-10-15 |
WO1994026249A1 (en) | 1994-11-24 |
DE69431433D1 (de) | 2002-10-31 |
EP0702551B1 (en) | 2002-09-25 |
AU687816B2 (en) | 1998-03-05 |
NO954437D0 (no) | 1995-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO954437D0 (no) | Preparater og metoder for reparasjon og forhindring av fibrotiske skader | |
HK186596A (en) | Pyridine and pyridine n-oxide derivatives of diarylmethyl-piperidines or piperazines compositions and use thereof | |
FI925342A (fi) | Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi | |
TR199802273T2 (xx) | Fibrotik lezyonlar�n onar�lmas� ve �nlenmesi. | |
MY112102A (en) | Therapeutic heterocycles. | |
IE790756L (en) | Cerebral therapeutic agent | |
DK0503440T3 (da) | Sumatriptanholdige lægemidler | |
ZA919317B (en) | Novel hydroxamic acid and N-hydroxyurea derivatives and their use. | |
ZA969621B (en) | Therapeutic compounds | |
DK122391D0 (da) | Terapeutisk aktiv, substitueret benzimidazolderivat og fysiologisk acceptable salte heraf samt fremgangsmaade til fremstilling af samme | |
CA2427814A1 (en) | A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders | |
BG105342A (en) | Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases | |
NZ535611A (en) | Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist | |
BR0017367A (pt) | Uso de melagatran ou de um seu derivado farmaceuticamente aceitável, método de tratamento de um distúrbio isquêmico em um paciente tendo, ou sob risco de ter, fibrilação atrial não-valvular, e, formulação farmacêutica | |
FR2688504B1 (fr) | Derives de 2-(piperidin-1-yl)ethanol, leur preparation et leur application en therapeutique. | |
TH13285EX (th) | สารประกอบที่ใช้บำบัดโรคที่เกี่ยวกับการเสื่อมของประสาท | |
FR2689891B3 (fr) | Derives de 2-(piperidin-1-yl)ethanol, leur preparation et leur application en therapeutique. |